Key Highlights
- FDA has greenlit Merck’s Lipfendra (enlicitide), marking the debut of a once-daily oral medication targeting PCSK9 for elevated LDL cholesterol
- Clinical studies demonstrated Lipfendra reduced LDL cholesterol by 60%, with no severe adverse reactions documented
- At $315 monthly, Merck’s pricing strategy significantly undercuts competing injectable options exceeding $500 per month
- Wall Street forecasters anticipate Lipfendra revenues crossing $350 million by 2027, with long-range potential hitting $5 billion yearly
- Guggenheim maintained its Buy recommendation with a $145 target price for MRK after encouraging Keytruda collaboration trial results
Merck shares advanced approximately 1% during Thursday’s premarket session to $125, following the FDA’s ahead-of-schedule authorization of Lipfendra — the inaugural oral PCSK9 blocker — through the regulatory body’s fast-track evaluation pathway. Year-to-date in 2026, the stock has climbed roughly 18%.
This regulatory clearance represents a significant achievement for Merck. Lipfendra, the commercial designation for enlicitide, becomes the first tablet formulation capable of blocking PCSK9, a protein responsible for regulating LDL cholesterol — widely recognized as harmful cholesterol. Previously, PCSK9 blocking medications existed exclusively as injectable treatments.
Heart and vascular conditions remain the primary mortality driver worldwide and represent approximately one-quarter of fatalities in the United States. Statin medications have dominated treatment protocols since the 1980s, yet they prove insufficient for numerous patients, especially individuals with genetic predisposition to elevated cholesterol.
Clinical investigations involving Lipfendra demonstrated a 60% reduction in LDL cholesterol concentrations. Severe side effects were absent, although roughly 7% of trial participants experienced diarrhea. An extended research study monitoring cardiovascular events including heart attacks and strokes continues but isn’t scheduled to conclude until 2029.
Competitive Landscape with Pricing Advantage
Merck is launching into a therapeutic space already occupied by injectable PCSK9 medications. Amgen’s Repatha achieved $900 million in first-quarter 2026 revenue, representing 34% year-over-year growth. Novartis’s Leqvio contributed $400 million during the identical timeframe, marking a 76% increase. Regeneron’s Praluent delivered $260 million in 2025 domestic sales.
Lipfendra’s monthly list price of $315 presents a compelling value proposition compared to injectable alternatives commanding prices exceeding $500. Merck announced commercial distribution will commence within several weeks.
Financial analysts forecast Lipfendra could generate more than $350 million in revenue during the upcoming year, with extended-term possibilities approaching $5 billion in annual sales assuming robust market adoption.
The medication also holds strategic significance. Merck’s powerhouse oncology treatment Keytruda — delivering $32 billion in yearly revenue — faces patent expiration in 2028. Lipfendra represents a critical component of Merck’s portfolio intended to compensate for that anticipated revenue decline.
Keytruda Development Portfolio Also Strengthened
In related developments, Guggenheim confirmed its Buy stance and $145 valuation target for MRK on Thursday, referencing favorable Phase 3 outcomes from collaborator Kelun-Biotech. The study evaluated Kelun’s TROP2-targeted antibody-drug conjugate sacituzumab tirumotecan combined with Keytruda for initial-line NSCLC patients presenting PD-L1 negative non-squamous malignancies.
The combination therapy delivered substantial enhancement in progression-free survival alongside encouraging overall survival indicators compared to the comparison group. Comprehensive findings are anticipated at October’s ESMO conference.
BMO Capital established a $142 valuation target for MRK. Scotiabank positioned itself higher at $155, referencing an enhanced multiple within its discounted cash flow modeling. MRK currently trades approaching its 52-week peak of $130.29.
AstraZeneca is similarly advancing a rival oral PCSK9 inhibitor designated laroprovstat, suggesting Lipfendra’s first-to-market position may encounter competition relatively soon.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
